Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dis-Chem PharmaciesJSE:DCP -0.36%86 Peter Lynch Fair Value is R11.58 as of Jul. 29, 2026, which is 100% below its 10-year median of 1.99. GuruFocus rates JSE:DCP with a GF Score™ of 86/100 and a GF Value™ of R38.34 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 170 Healthcare Providers & Services companies, Dis-Chem Pharmacies ranks worse than 80.59% on this metric.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, Dis-Chem Pharmacies's PEG is 1. Dis-Chem Pharmacies's 5-Year TTM EBITDA Growth Rate is 10.19.
Dis-Chem Pharmacies's EPS without NRI for the trailing twelve months (TTM) ended in Feb. 2026 was R1.14. Therefore, the Peter Lynch Fair Value for today is R11.58.
The historical rank and industry rank for Dis-Chem Pharmacies's Peter Lynch Fair Value or its related term are showing as below:
JSE:DCP'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.51 Med: 1.99 Max: 3.2
Current: 2.61
During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of Dis-Chem Pharmacies was 3.20. The lowest was 1.51. And the median was 1.99.
JSE:DCP's Price-to-Peter-Lynch-Fair-Value is ranked worse than 80.59% of 170
companies
in the Healthcare Providers & Services industry
Industry Median: 1.215
vs JSE:DCP: 2.61
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
Dis-Chem Pharmacies (JSE:DCP) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 10.19 instead of 15 in this case.
Dis-Chem Pharmacies's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
30.19
/
11.58
=
2.61
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dis-Chem Pharmacies Peter Lynch Fair Value Related Terms
Dis-Chem Pharmacies Peter Lynch Fair Value Historical Data
* Premium members only.
The historical data trend for Dis-Chem Pharmacies's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dis-Chem Pharmacies Peter Lynch Fair Value Competitor Comparison
For the Pharmaceutical Retailers subindustry, Dis-Chem Pharmacies's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dis-Chem Pharmacies Price-to-Peter-Lynch-Fair-Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Dis-Chem Pharmacies's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where Dis-Chem Pharmacies's Price-to-Peter-Lynch-Fair-Value falls into.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Dis-Chem Pharmacies's EPS without NRI for the trailing twelve months (TTM) ended in Feb. 2026 was R1.14.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
What does a Peter Lynch Fair Value of R11.58 mean?
Dis-Chem Pharmacies (JSE:DCP) has a Peter Lynch Fair Value of R11.58 as of Jul. 29, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Dis-Chem Pharmacies and its competitors. This is 482% above median its historical median of 1.99. Over the past decade, Dis-Chem Pharmacies' Peter Lynch Fair Value has ranged from 1.51 to 3.20. According to the industry distribution chart, Dis-Chem Pharmacies ranks #137 out of 170 companies in the Healthcare Providers & Services industry, placing it in the top 80.6%.
Is Dis-Chem Pharmacies' Peter Lynch Fair Value too high?
Dis-Chem Pharmacies' current Peter Lynch Fair Value of R11.58 is 482% above median its 10-year median of 1.99. Over the past 10 years, this metric has ranged from a low of 1.51 to a high of 3.20. Based on the distribution chart, Dis-Chem Pharmacies ranks #137 out of 170 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Dis-Chem Pharmacies has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dis-Chem Pharmacies' Peter Lynch Fair Value compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Dis-Chem Pharmacies ranks #137 out of 170 companies for Peter Lynch Fair Value. This places Dis-Chem Pharmacies in the lower half of its industry. The industry median Peter Lynch Fair Value is 1.22. Historically, Dis-Chem Pharmacies' own Peter Lynch Fair Value has ranged from 1.51 to 3.20 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Healthcare Providers & Services company?
The median Peter Lynch Fair Value among Healthcare Providers & Services companies is 1.22, based on 170 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Dis-Chem Pharmacies and its competitors. For the Healthcare Providers & Services industry, the median Peter Lynch Fair Value is 1.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dis-Chem Pharmacies's current Peter Lynch Fair Value is R11.58, which is 482% above median its own 10-year median of 1.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dis-Chem Pharmacies stock overvalued right now?
Based on GuruFocus' analysis, Dis-Chem Pharmacies (JSE:DCP) is currently considered Modestly Undervalued. The stock's GF Value™ is R38.34, compared to a current price of R30.19 — trading 21.3% below its estimated fair value. The current Peter Lynch Fair Value is R11.58, which is 482% above median its 10-year median of 1.99. Dis-Chem Pharmacies' overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For Dis-Chem Pharmacies (JSE:DCP), the current Peter Lynch Fair Value is R11.58 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dis-Chem Pharmacies (JSE:DCP) Overvalued in 2026?
Based on GuruFocus' analysis, Dis-Chem Pharmacies stock appears to be undervalued.
The current stock price of R30.19 is trading 21.3% below its estimated GF Value™ of R38.34.
GuruFocus considers Dis-Chem Pharmacies to be Modestly Undervalued.
Key valuation signals for JSE:DCP:
Peter Lynch Fair Value: R11.58 (482% above median its 10-year median of 1.99)
GF Value™: R38.34 vs. price of R30.19 (21.3% below fair value)
No single metric tells the full story. See the JSE:DCP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dis-Chem Pharmacies Ltd is a pharmaceutical company based in South Africa. Its product portfolio includes personal care products, beauty products, healthcare and nutrition products, and dispensary and baby care products. The operating segments of the group are Retail and Wholesale. It derives maximum revenue from the Retail segment, which includes company stores, retailers of pharmaceuticals and a variety of health and beauty products, as well as pharma-logistic services and oncology and retailers of pharmaceutical products. The Wholesale segment consists of the CJ wholesale and company distribution businesses, wholesalers of pharmaceuticals, and a variety of health and beauty products. Geographically, the group carries out its business operations principally in South Africa.
86GF Score
Get the complete analysis for JSE:DCP
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:DCP has been successfully added to your 
